EAGER: Design and Validation of a Point-of-Care Device To Detect Biomarkers of Pain

EAGER：设计和验证用于检测疼痛生物标志物的护理点设备

• 批准号: 1842670
• 负责人: Stefan Bossmann
• 金额: $ 30万
• 依托单位: Kansas State University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2022-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1842670&HistoricalAwards=false
• 关键词: EAGER; Design; Validation; Point; Care

Currently, there are no POC (Point of Care) sensing platforms available to individuals to monitor a patient's biological response to pain, disease triggers, airborne irritants, toxins, or the recurrence of an infectious disease or cancer, by direct and rapid profiling of critical biomarkers that may be present in biofluid samples. Such biomarker-based diagnostics could have numerous applications in precision medicine, among them precision pain management and the reduction of opioid abuse. This project will design, build, and validate a microfluidic point-of-care (POC) device that will separate, identify and quantify cytokines that are markers for pain. The device will analyze biomarkers of pain in all types of liquid biopsies.This research will focus on the detection of biomarkers for pain in the serum of a rat model. The cytokines will be identified at the required ultralow concentrations through binding to targeting peptide sequences featuring fluorescent labels and subsequent separation by means of Isoelectric Focusing (IEF). It is well established that pro- and anti-inflammatory cytokines correlate with the perception of pain. Therefore, the proposed POC-device will make pain "quantifiable" and enable precision pain management. The team of investigators will combine the required expertise in neuroscience, drug addiction and pain research (Dr. Cunningham), Biophotonics and medical device development (Dr. Motamedi), microfluidic technology and IEF device development (Dr. Culbertson), and biological chemistry, bioengineering, and Biophotonics (Dr. Bossmann, PI).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

当前，个人没有可用于监测患者对疼痛，疾病触发因素，空中刺激性，毒素或传染病或癌症的复发的POC（护理点）传感平台，通过直接和快速分析关键的生物标志物，这些生物标志物可能存在于生物含量样品中。这种基于生物标志物的诊断可能在精确医学中有许多应用，其中包括精确疼痛管理和减少阿片类药物滥用。该项目将设计，构建和验证一个微流体保健点（POC）设备，该设备将分开，识别和量化为疼痛标记的细胞因子。该设备将分析所有类型的液体活检中疼痛的生物标志物。这项研究将重点放在大鼠模型血清中疼痛的生物标志物检测上。通过与具有荧光标签的靶向肽序列结合，并通过等电聚焦（IEF）结合靶向肽序列，在所需的超高浓度下鉴定细胞因子。众所周知，促和抗炎细胞因子与疼痛的感知相关。因此，拟议的POC设备将使疼痛“可量化”，并实现精确的疼痛管理。调查人员团队将结合神经科学，药物成瘾和疼痛研究（坎宁安博士），生物摄影和医疗设备开发（Motamedi博士），微流体技术和IEF设备开发（Culbertson博士），生物学化学，生物工程和生物植物的生物化学和生物指令（Bossmann，PI The STHIS nsfors and Readery aftery and the saterfory）。通过使用基金会的智力优点和更广泛影响的评论标准进行评估。

项目成果

Optical biosensing of markers of mucosal inflammation.

• DOI: 10.1016/j.nano.2021.102476
• 发表时间: 2022-03
• 期刊: NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
• 影响因子: 5.4
• 作者: Covarrubias-Zambrano, Obdulia;Motamedi, Massoud;Ameredes, Bill T.;Tian, Bing;Calhoun, William J.;Zhao, Yingxin;Brasier, Allan R.;Kalubowilage, Madumali;Malalasekera, Aruni P.;Yapa, Asanka S.;Wang, Hongwang;Culbertson, Christopher T.;Troyer, Deryl L.;Bossmann, Stefan H.
• 通讯作者: Bossmann, Stefan H.

Impacts of Behavioral Biases on Active Learning Strategies

行为偏差对主动学习策略的影响

• DOI: 10.1109/icaiic54071.2022.9722689
• 发表时间: 2022
• 期刊: 2022 International Conference on Artificial Intelligence in Information and Communication (ICAIIC
• 作者: Agarwal, Deepesh;Covarrubias-Zambrano, Obdulia;Bossmann, Stefan;Natarajan, Balasubramaniam
• 通讯作者: Natarajan, Balasubramaniam

Early detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis

通过超灵敏蛋白酶活性分析在液体活检中早期检测非小细胞肺癌

• DOI: 10.20517/2394-4722.2020.45
• 发表时间: 2020
• 期刊: Journal of Cancer Metastasis and Treatment
• 作者: Udukala, Dinusha N.;Wendel, Sebastian O.;Wang, Hongwang;Yapa, Asanka S.;Covarrubias-Zambrano, Obdulia;Janik, Katharine;Gadbury, Gary;Troyer, Deryl L.;Bossmann, Stefan H.
• 通讯作者: Bossmann, Stefan H.